What's Going On With Aurinia Pharmaceuticals Stock?
Portfolio Pulse from Adam Eckert
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares have risen, continuing a trend following Otsuka Pharmaceutical's filing of a new drug application (NDA) for voclosporin in Japan. Aurinia, which partnered with Otsuka in 2020, stands to receive a $10 million payment and royalties upon approval. The FDA approved voclosporin in early 2021, and it is available in the U.S. as LUPKYNIS. Aurinia is currently trending on social platforms and was the top ticker on Stocktwits.
November 20, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals' stock is experiencing an uptrend after its partner Otsuka filed an NDA in Japan for voclosporin, with potential financial benefits for Aurinia upon approval.
The positive stock movement for AUPH is directly related to the NDA filing by Otsuka, which could lead to significant financial gains for Aurinia. The anticipation of a $10 million payment and future royalties creates a bullish sentiment among investors, which is likely to support the stock's short-term performance. The stock's trending status on social platforms may also contribute to increased investor interest and trading volume.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100